The importance of effectively assessing and treating mood disorders cannot be overstated. Objectivity is a key element to the therapeutic approach to mood disorders. Currently, the standard of care dictates a trial and error pharmaceutical approach is taken with each patient based on both self and clinician assessments. However, without information yielded from objective clinical testing, selection of the most effective treatment for each particular patient with a mood disorder continues to be a challenge. While this may prove effective for some patients, the potential for harm during those interim treatment failures is a real concern for clinicians and patients alike.
These neurotransmitters communicate with one another in relation to their effects on mood disorders, hormones, sleep, glucose/insulin balance, pain perception, appetite, and cognitive function.
The Neurotransmitter-Intermediate Profile is a four point urine analyses test, assessing levels of nine neurotransmitters which include: Serotonin, GABA, Dopamine, Noradrenaline, Adrenaline, Glutamate, ratio, PEA, Glycine and Histamine.
The report format includes a correlation analysis section, written by the clinical department, which relates the patients’ symptoms with their corresponding lab results, as an aide to the practitioner.
Targeted neurotransmitter testing can help health care practitioners achieve a diagnostic edge beyond the traditional psychological inventory by identifying specific imbalances in neurotransmitter levels. Based on neurotransmitter test results, practitioners can identify specific biochemical heterogeneities for each particular patient, and objectively monitor therapeutic responses during and after intervention.
- Poor concentration
- Poor memory
- Lack of motivation and energy
- Mood swings
- Thyroid disorders
- Hormonal Imbalances
- GIT issues